Forte Biosciences (FBRX) Total Liabilities (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Total Liabilities of $25.1 million for Q1 2026, down 47.06% year-over-year from $47.5 million in Q1 2025, and up 15.31% quarter-over-quarter from $21.8 million in Q4 2025.
Forte Biosciences (FBRX) Total Liabilities (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Total Liabilities for 11 consecutive years, with $25.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities fell 47.06% year-over-year to $25.1 million; the TTM figure through Mar 2026 stood at $25.1 million (down 47.06% YoY), while the FY2025 annual figure was $21.8 million, up 139.93% from the prior year.
- Total Liabilities climbed to $25.1 million in Q1 2026 per FBRX's latest filing, from $21.8 million in the prior quarter.
- Across five years, Total Liabilities topped out at $107.8 million in Q2 2025 and bottomed at $9.1 million in Q4 2024.
- Historically, Total Liabilities has averaged $41.6 million across 5 years, with a median of $39.0 million in 2023.
- Annual changes were most pronounced in 2024 — Total Liabilities slumped 76.7% — and 2025, when it surged 441.01%.
- Forte Biosciences' Total Liabilities stood at $42.0 million in 2022, then fell by 7.18% to $39.0 million in 2023, then plunged by 76.7% to $9.1 million in 2024, then jumped by 139.93% to $21.8 million in 2025, then climbed by 15.31% to $25.1 million in 2026.
- Business Quant data shows FBRX's Total Liabilities at $25.1 million in Q1 2026, $21.8 million in Q4 2025, and $97.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | 21.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.95 Mn |
| Mar 31, 2026 | 25.12 Mn |
| Dec 31, 2025 | 21.79 Mn |
| Sep 30, 2025 | 97.09 Mn |
| Jun 30, 2025 | 107.78 Mn |
| Mar 31, 2025 | 47.46 Mn |
| Dec 31, 2024 | 9.08 Mn |
| Sep 30, 2024 | 17.95 Mn |
| Jun 30, 2024 | 26.08 Mn |
| Mar 31, 2024 | 32.02 Mn |
| Dec 31, 2023 | 38.98 Mn |
| Sep 30, 2023 | 47.88 Mn |
| Jun 30, 2023 | 31.18 Mn |
| Mar 31, 2023 | 36.71 Mn |
| Dec 31, 2022 | 42.00 Mn |
| Sep 30, 2022 | 45.13 Mn |
| Jun 30, 2022 | 39.72 Mn |
| Mar 31, 2022 | 41.30 Mn |
| Dec 31, 2021 | 43.31 Mn |
| Sep 30, 2021 | 47.39 Mn |